Company intelligence / Profile preview

Aillis

Ownership: Private
Development stage: Commercial

Overview

Aillis has developed nodoca™, an AI-powered medical device that captures images of the throat (pharynx) and analyzes them using artificial intelligence to assist in the early and accurate detection of influenza. The system eliminates the need for traditional swab collection, providing a non-invasive alternative. Clinical results indicate high accuracy in detecting influenza from pharyngeal images combined with physician interviews.

Therapeutic areas: Infectious Diseases
Modalities: DeviceArtificial intelligence (AI)-based diagnostic tool
Industry: Medical Imaging

Drug pipeline

1 asset

nodoca

Commercial

Indications: Influenza

Partnerships

Anritsu (wireless connectivity evaluation partner)

Beyond the preview

Go deeper on Aillis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aillis.

Explore the full profile